Notably, analysis of the University of Toronto Meningioma dataset from cBioportal revealed a correlation between higher IL6 mRNA levels and increased tumour recurrence: 65.6% (40/61) of patients in the top half of IL6 expression develop recurrence, compared with 40.0% (24/60) in the bottom half (p = 0.0063, Fig. 8h), especially in grade 1(p = 0.0462, Fig. 8I), but not in grade 2 or 3 (Supplementary Fig. 8a, b). This evidence concerns the gene IL6 and meningioma.